You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Guidelines & Advice

About Guidelines Email Guidelines Team

Displaying Guidelines

355 Items

Maximal Androgen Blockade for the Treatment of Metastatic Prostate Cancer

Document Status: Archived
ID: 3-1

Nov 2011

Molecular Analyses in the Diagnosis, Prognosis, and Selection of Therapy in non-GIST Soft Tissue Sarcomas

Document Status: Archived
ID: GL 11-12

Apr 2018

Multidisciplinary Cancer Conference Standards

Document Status: Current
ID: MCC

Jun 2006

Multidisciplinary Specialist Care for Sarcoma

Document Status: Archived
ID: 11-9

Oct 2014

Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma

Document Status: Current
ID: GL 4-1
Version: 2

Jan 2021

Neoadjuvant or Adjuvant Therapy for Resectable Gastric Cancer

Document Status: Archived
ID: 2-14
Version: 3

Apr 2011

Non-Surgical Management of Advanced Hepatocellular Carcinoma

Document Status: In-Review
ID: GL 2-24

May 2019

Oncology Caregiver Support Framework

Document Status: Current
ID: N/A
Version: N/A

Oct 2019

Oncology Nursing Telepractice Standards

Document Status: Current
Version: N/A

Aug 2019

Ontario Health (Cancer Care Ontario) Endorsement of ASCO Rapid Recommendation on 177Lutetium-Prostate-Specific Membrane Antigen-617 (PSMA-617) for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Document Status: Current
ID: GL-END 3-25

Nov 2023

Ontario Oncology Information System Standards: Defining its Meaningful Use

Document Status: Current
ID: GL-C50-14

Mar 2014

Optimal Systemic Therapy for Early Female Breast Cancer

Document Status: In-Review
ID: 1-21

Sep 2014